Advertisement

Index by author

May 01, 1993; Volume 43,Issue 5

A

  1. Arndts, D

    1. Novel potent inhibitor of receptor-activated nonselective cation currents in HL-60 cells.
      D Krautwurst, J Hescheler, D Arndts, W Lösel, R Hammer and G Schultz
      Molecular Pharmacology May 1993, 43 (5) 655-659;

  2. Artymyshyn, R P

    1. Development of polyclonal anti-D2 dopamine receptor antibodies using sequence-specific peptides.
      V A Boundy, R R Luedtke, R P Artymyshyn, T M Filtz and P B Molinoff
      Molecular Pharmacology May 1993, 43 (5) 666-676;

  3. Azoulay, D

    1. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver.
      A Lemoine, J C Gautier, D Azoulay, L Kiffel, C Belloc, F P Guengerich, P Maurel, P Beaune and J P Leroux
      Molecular Pharmacology May 1993, 43 (5) 827-832;

B

  1. Beaune, P

    1. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver.
      A Lemoine, J C Gautier, D Azoulay, L Kiffel, C Belloc, F P Guengerich, P Maurel, P Beaune and J P Leroux
      Molecular Pharmacology May 1993, 43 (5) 827-832;

  2. Belloc, C

    1. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver.
      A Lemoine, J C Gautier, D Azoulay, L Kiffel, C Belloc, F P Guengerich, P Maurel, P Beaune and J P Leroux
      Molecular Pharmacology May 1993, 43 (5) 827-832;

  3. Berger, S H

    1. Variation in human thymidylate synthase is associated with resistance to 5-fluoro-2'-deoxyuridine.
      S T Davis and S H Berger
      Molecular Pharmacology May 1993, 43 (5) 702-708;

  4. Bossé, R

    1. Photoaffinity labeling of subtype 2 angiotensin receptor of human myometrium.
      G Servant, G Boulay, R Bossé, E Escher and G Guillemette
      Molecular Pharmacology May 1993, 43 (5) 677-683;

  5. Boulay, G

    1. Photoaffinity labeling of subtype 2 angiotensin receptor of human myometrium.
      G Servant, G Boulay, R Bossé, E Escher and G Guillemette
      Molecular Pharmacology May 1993, 43 (5) 677-683;

  6. Boundy, V A

    1. Development of polyclonal anti-D2 dopamine receptor antibodies using sequence-specific peptides.
      V A Boundy, R R Luedtke, R P Artymyshyn, T M Filtz and P B Molinoff
      Molecular Pharmacology May 1993, 43 (5) 666-676;

  7. Bowlby, M R

    1. Pregnenolone sulfate potentiation of N-methyl-D-aspartate receptor channels in hippocampal neurons.
      M R Bowlby
      Molecular Pharmacology May 1993, 43 (5) 813-819;

  8. Buckley, N J

    1. Differential regulation of muscarinic receptor mRNA levels in neuroblastoma cells by chronic agonist exposure: a comparative polymerase chain reaction study.
      M C Steel and N J Buckley
      Molecular Pharmacology May 1993, 43 (5) 694-701;

C

  1. Capranico, G

    1. Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects.
      P De Isabella, G Capranico, M Palumbo, C Sissi, A P Krapcho and F Zunino
      Molecular Pharmacology May 1993, 43 (5) 715-721;

  2. Carter, D B

    1. Comparison of interactions of [3H]muscimol, t-butylbicyclophosphoro[35S]thionate, and [3H]flunitrazepam with cloned gamma-aminobutyric acidA receptors of the alpha 1 beta 2 and alpha 1 beta 2 gamma 2 subtypes.
      J F Pregenzer, W B Im, D B Carter and D R Thomsen
      Molecular Pharmacology May 1993, 43 (5) 801-806;

  3. Choudhary, M S

    1. A single point mutation (Phe340-->Leu340) of a conserved phenylalanine abolishes 4-[125I]iodo-(2,5-dimethoxy)phenylisopropylamine and [3H]mesulergine but not [3H]ketanserin binding to 5-hydroxytryptamine2 receptors.
      M S Choudhary, S Craigo and B L Roth
      Molecular Pharmacology May 1993, 43 (5) 755-761;

  4. Coy, D H

    1. Characterization of bombesin receptors using a novel, potent, radiolabeled antagonist that distinguishes bombesin receptor subtypes.
      S Mantey, H Frucht, D H Coy and R T Jensen
      Molecular Pharmacology May 1993, 43 (5) 762-774;

  5. Craigo, S

    1. A single point mutation (Phe340-->Leu340) of a conserved phenylalanine abolishes 4-[125I]iodo-(2,5-dimethoxy)phenylisopropylamine and [3H]mesulergine but not [3H]ketanserin binding to 5-hydroxytryptamine2 receptors.
      M S Choudhary, S Craigo and B L Roth
      Molecular Pharmacology May 1993, 43 (5) 755-761;

D

  1. Davis, S T

    1. Variation in human thymidylate synthase is associated with resistance to 5-fluoro-2'-deoxyuridine.
      S T Davis and S H Berger
      Molecular Pharmacology May 1993, 43 (5) 702-708;

  2. De Isabella, P

    1. Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects.
      P De Isabella, G Capranico, M Palumbo, C Sissi, A P Krapcho and F Zunino
      Molecular Pharmacology May 1993, 43 (5) 715-721;

  3. De Léan, A

    1. Development of natriuretic peptide analogs selective for the atrial natriuretic factor-R1A receptor subtype.
      M Mimeault, A Fournier, J Féthiere and A De Léan
      Molecular Pharmacology May 1993, 43 (5) 775-782;

  4. Dionne, V E

    1. Modulation by albumin of neuronal cholinergic sensitivity.
      D Gurantz, J F Margiotta, A T Harootunian and V E Dionne
      Molecular Pharmacology May 1993, 43 (5) 807-812;

E

  1. Eriksson, A

    1. Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors.
      A Malmberg, D M Jackson, A Eriksson and N Mohell
      Molecular Pharmacology May 1993, 43 (5) 749-754;

  2. Escher, E

    1. Photoaffinity labeling of subtype 2 angiotensin receptor of human myometrium.
      G Servant, G Boulay, R Bossé, E Escher and G Guillemette
      Molecular Pharmacology May 1993, 43 (5) 677-683;

F

  1. Ferry, R C

    1. Effects of agonists, partial agonists, and antagonists on the regulation of 5-hydroxytryptamine2 receptors in P11 cells.
      R C Ferry, C D Unsworth and P B Molinoff
      Molecular Pharmacology May 1993, 43 (5) 726-733;

  2. Féthiere, J

    1. Development of natriuretic peptide analogs selective for the atrial natriuretic factor-R1A receptor subtype.
      M Mimeault, A Fournier, J Féthiere and A De Léan
      Molecular Pharmacology May 1993, 43 (5) 775-782;

  3. Filtz, T M

    1. Development of polyclonal anti-D2 dopamine receptor antibodies using sequence-specific peptides.
      V A Boundy, R R Luedtke, R P Artymyshyn, T M Filtz and P B Molinoff
      Molecular Pharmacology May 1993, 43 (5) 666-676;

  4. Fournier, A

    1. Development of natriuretic peptide analogs selective for the atrial natriuretic factor-R1A receptor subtype.
      M Mimeault, A Fournier, J Féthiere and A De Léan
      Molecular Pharmacology May 1993, 43 (5) 775-782;

  5. Frucht, H

    1. Characterization of bombesin receptors using a novel, potent, radiolabeled antagonist that distinguishes bombesin receptor subtypes.
      S Mantey, H Frucht, D H Coy and R T Jensen
      Molecular Pharmacology May 1993, 43 (5) 762-774;

G

  1. Gautier, J C

    1. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver.
      A Lemoine, J C Gautier, D Azoulay, L Kiffel, C Belloc, F P Guengerich, P Maurel, P Beaune and J P Leroux
      Molecular Pharmacology May 1993, 43 (5) 827-832;

  2. Gibson, G G

    1. Isolation and expression of a cDNA coding for rat kidney cytosolic cysteine conjugate beta-lyase.
      S J Perry, M A Schofield, M MacFarlane, E A Lock, L J King, G G Gibson and P S Goldfarb
      Molecular Pharmacology May 1993, 43 (5) 660-665;

  3. Gilbert, T

    1. Isolation of glucagon antagonists by random molecular mutagenesis and screening.
      R A Smith, R Sisk, P Lockhart, S Mathewes, T Gilbert, K Walker and J Piggot
      Molecular Pharmacology May 1993, 43 (5) 741-748;

  4. Goldfarb, P S

    1. Isolation and expression of a cDNA coding for rat kidney cytosolic cysteine conjugate beta-lyase.
      S J Perry, M A Schofield, M MacFarlane, E A Lock, L J King, G G Gibson and P S Goldfarb
      Molecular Pharmacology May 1993, 43 (5) 660-665;

  5. Gonzalez, F J

    1. Marked endogenous activation of the CYP1A1 and CYP1A2 genes in the congenitally jaundiced Gunn rat.
      J Kapitulnik and F J Gonzalez
      Molecular Pharmacology May 1993, 43 (5) 722-725;

  6. Guengerich, F P

    1. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver.
      A Lemoine, J C Gautier, D Azoulay, L Kiffel, C Belloc, F P Guengerich, P Maurel, P Beaune and J P Leroux
      Molecular Pharmacology May 1993, 43 (5) 827-832;

  7. Guillemette, G

    1. Photoaffinity labeling of subtype 2 angiotensin receptor of human myometrium.
      G Servant, G Boulay, R Bossé, E Escher and G Guillemette
      Molecular Pharmacology May 1993, 43 (5) 677-683;

  8. Gurantz, D

    1. Modulation by albumin of neuronal cholinergic sensitivity.
      D Gurantz, J F Margiotta, A T Harootunian and V E Dionne
      Molecular Pharmacology May 1993, 43 (5) 807-812;

H

  1. Hammer, R

    1. Novel potent inhibitor of receptor-activated nonselective cation currents in HL-60 cells.
      D Krautwurst, J Hescheler, D Arndts, W Lösel, R Hammer and G Schultz
      Molecular Pharmacology May 1993, 43 (5) 655-659;

  2. Harootunian, A T

    1. Modulation by albumin of neuronal cholinergic sensitivity.
      D Gurantz, J F Margiotta, A T Harootunian and V E Dionne
      Molecular Pharmacology May 1993, 43 (5) 807-812;

  3. Hering, S

    1. Extracellular localization of the benzothiazepine binding domain of L-type Ca2+ channels.
      S Hering, A Savchenko, C Strübing, M Lakitsch and J Striessnig
      Molecular Pharmacology May 1993, 43 (5) 820-826;

  4. Hescheler, J

    1. Novel potent inhibitor of receptor-activated nonselective cation currents in HL-60 cells.
      D Krautwurst, J Hescheler, D Arndts, W Lösel, R Hammer and G Schultz
      Molecular Pharmacology May 1993, 43 (5) 655-659;

I

  1. Im, W B

    1. Comparison of interactions of [3H]muscimol, t-butylbicyclophosphoro[35S]thionate, and [3H]flunitrazepam with cloned gamma-aminobutyric acidA receptors of the alpha 1 beta 2 and alpha 1 beta 2 gamma 2 subtypes.
      J F Pregenzer, W B Im, D B Carter and D R Thomsen
      Molecular Pharmacology May 1993, 43 (5) 801-806;

J

  1. Jackson, D M

    1. Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors.
      A Malmberg, D M Jackson, A Eriksson and N Mohell
      Molecular Pharmacology May 1993, 43 (5) 749-754;

  2. Jensen, R T

    1. Characterization of bombesin receptors using a novel, potent, radiolabeled antagonist that distinguishes bombesin receptor subtypes.
      S Mantey, H Frucht, D H Coy and R T Jensen
      Molecular Pharmacology May 1993, 43 (5) 762-774;

K

  1. Kapitulnik, J

    1. Marked endogenous activation of the CYP1A1 and CYP1A2 genes in the congenitally jaundiced Gunn rat.
      J Kapitulnik and F J Gonzalez
      Molecular Pharmacology May 1993, 43 (5) 722-725;

  2. Kiffel, L

    1. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver.
      A Lemoine, J C Gautier, D Azoulay, L Kiffel, C Belloc, F P Guengerich, P Maurel, P Beaune and J P Leroux
      Molecular Pharmacology May 1993, 43 (5) 827-832;

  3. King, L J

    1. Isolation and expression of a cDNA coding for rat kidney cytosolic cysteine conjugate beta-lyase.
      S J Perry, M A Schofield, M MacFarlane, E A Lock, L J King, G G Gibson and P S Goldfarb
      Molecular Pharmacology May 1993, 43 (5) 660-665;

  4. Kirkland, J L

    1. Tamoxifen stimulates expression of the c-fos proto-oncogene in rodent uterus.
      J L Kirkland, L Murthy and G M Stancel
      Molecular Pharmacology May 1993, 43 (5) 709-714;

  5. Krapcho, A P

    1. Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects.
      P De Isabella, G Capranico, M Palumbo, C Sissi, A P Krapcho and F Zunino
      Molecular Pharmacology May 1993, 43 (5) 715-721;

  6. Krautwurst, D

    1. Novel potent inhibitor of receptor-activated nonselective cation currents in HL-60 cells.
      D Krautwurst, J Hescheler, D Arndts, W Lösel, R Hammer and G Schultz
      Molecular Pharmacology May 1993, 43 (5) 655-659;

L

  1. Lakitsch, M

    1. Extracellular localization of the benzothiazepine binding domain of L-type Ca2+ channels.
      S Hering, A Savchenko, C Strübing, M Lakitsch and J Striessnig
      Molecular Pharmacology May 1993, 43 (5) 820-826;

  2. Law, P Y

    1. delta-Opioid receptor activates cAMP phosphodiesterase activities in neuroblastoma x glioma NG108-15 hybrid cells.
      P Y Law and H H Loh
      Molecular Pharmacology May 1993, 43 (5) 684-693;

  3. Lemoine, A

    1. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver.
      A Lemoine, J C Gautier, D Azoulay, L Kiffel, C Belloc, F P Guengerich, P Maurel, P Beaune and J P Leroux
      Molecular Pharmacology May 1993, 43 (5) 827-832;

  4. Leroux, J P

    1. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver.
      A Lemoine, J C Gautier, D Azoulay, L Kiffel, C Belloc, F P Guengerich, P Maurel, P Beaune and J P Leroux
      Molecular Pharmacology May 1993, 43 (5) 827-832;

  5. Lock, E A

    1. Isolation and expression of a cDNA coding for rat kidney cytosolic cysteine conjugate beta-lyase.
      S J Perry, M A Schofield, M MacFarlane, E A Lock, L J King, G G Gibson and P S Goldfarb
      Molecular Pharmacology May 1993, 43 (5) 660-665;

  6. Lockhart, P

    1. Isolation of glucagon antagonists by random molecular mutagenesis and screening.
      R A Smith, R Sisk, P Lockhart, S Mathewes, T Gilbert, K Walker and J Piggot
      Molecular Pharmacology May 1993, 43 (5) 741-748;

  7. Loh, H H

    1. delta-Opioid receptor activates cAMP phosphodiesterase activities in neuroblastoma x glioma NG108-15 hybrid cells.
      P Y Law and H H Loh
      Molecular Pharmacology May 1993, 43 (5) 684-693;

  8. Lösel, W

    1. Novel potent inhibitor of receptor-activated nonselective cation currents in HL-60 cells.
      D Krautwurst, J Hescheler, D Arndts, W Lösel, R Hammer and G Schultz
      Molecular Pharmacology May 1993, 43 (5) 655-659;

  9. Luedtke, R R

    1. Development of polyclonal anti-D2 dopamine receptor antibodies using sequence-specific peptides.
      V A Boundy, R R Luedtke, R P Artymyshyn, T M Filtz and P B Molinoff
      Molecular Pharmacology May 1993, 43 (5) 666-676;

  10. Lynch, C

    1. Inhalational anesthetic actions on voltage-gated ion currents of bovine adrenal chromaffin cells.
      J J Pancrazio, W K Park and C Lynch
      Molecular Pharmacology May 1993, 43 (5) 783-794;

M

  1. MacFarlane, M

    1. Isolation and expression of a cDNA coding for rat kidney cytosolic cysteine conjugate beta-lyase.
      S J Perry, M A Schofield, M MacFarlane, E A Lock, L J King, G G Gibson and P S Goldfarb
      Molecular Pharmacology May 1993, 43 (5) 660-665;

  2. Malmberg, A

    1. Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors.
      A Malmberg, D M Jackson, A Eriksson and N Mohell
      Molecular Pharmacology May 1993, 43 (5) 749-754;

  3. Mantey, S

    1. Characterization of bombesin receptors using a novel, potent, radiolabeled antagonist that distinguishes bombesin receptor subtypes.
      S Mantey, H Frucht, D H Coy and R T Jensen
      Molecular Pharmacology May 1993, 43 (5) 762-774;

  4. Margiotta, J F

    1. Modulation by albumin of neuronal cholinergic sensitivity.
      D Gurantz, J F Margiotta, A T Harootunian and V E Dionne
      Molecular Pharmacology May 1993, 43 (5) 807-812;

  5. Mathewes, S

    1. Isolation of glucagon antagonists by random molecular mutagenesis and screening.
      R A Smith, R Sisk, P Lockhart, S Mathewes, T Gilbert, K Walker and J Piggot
      Molecular Pharmacology May 1993, 43 (5) 741-748;

  6. Maurel, P

    1. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver.
      A Lemoine, J C Gautier, D Azoulay, L Kiffel, C Belloc, F P Guengerich, P Maurel, P Beaune and J P Leroux
      Molecular Pharmacology May 1993, 43 (5) 827-832;

  7. Mimeault, M

    1. Development of natriuretic peptide analogs selective for the atrial natriuretic factor-R1A receptor subtype.
      M Mimeault, A Fournier, J Féthiere and A De Léan
      Molecular Pharmacology May 1993, 43 (5) 775-782;

  8. Mohell, N

    1. Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors.
      A Malmberg, D M Jackson, A Eriksson and N Mohell
      Molecular Pharmacology May 1993, 43 (5) 749-754;

  9. Molinoff, P B

    1. Development of polyclonal anti-D2 dopamine receptor antibodies using sequence-specific peptides.
      V A Boundy, R R Luedtke, R P Artymyshyn, T M Filtz and P B Molinoff
      Molecular Pharmacology May 1993, 43 (5) 666-676;
    2. Effects of agonists, partial agonists, and antagonists on the regulation of 5-hydroxytryptamine2 receptors in P11 cells.
      R C Ferry, C D Unsworth and P B Molinoff
      Molecular Pharmacology May 1993, 43 (5) 726-733;

  10. Murthy, L

    1. Tamoxifen stimulates expression of the c-fos proto-oncogene in rodent uterus.
      J L Kirkland, L Murthy and G M Stancel
      Molecular Pharmacology May 1993, 43 (5) 709-714;

N

  1. Neubig, R R

    1. Subsecond modulation of formyl peptide-linked guanine nucleotide-binding proteins by guanosine 5'-O-(3-thio)triphosphate in permeabilized neutrophils.
      R R Neubig and L A Sklar
      Molecular Pharmacology May 1993, 43 (5) 734-740;

P

  1. Palumbo, M

    1. Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects.
      P De Isabella, G Capranico, M Palumbo, C Sissi, A P Krapcho and F Zunino
      Molecular Pharmacology May 1993, 43 (5) 715-721;

  2. Pancrazio, J J

    1. Inhalational anesthetic actions on voltage-gated ion currents of bovine adrenal chromaffin cells.
      J J Pancrazio, W K Park and C Lynch
      Molecular Pharmacology May 1993, 43 (5) 783-794;

  3. Park, W K

    1. Inhalational anesthetic actions on voltage-gated ion currents of bovine adrenal chromaffin cells.
      J J Pancrazio, W K Park and C Lynch
      Molecular Pharmacology May 1993, 43 (5) 783-794;

  4. Perry, S J

    1. Isolation and expression of a cDNA coding for rat kidney cytosolic cysteine conjugate beta-lyase.
      S J Perry, M A Schofield, M MacFarlane, E A Lock, L J King, G G Gibson and P S Goldfarb
      Molecular Pharmacology May 1993, 43 (5) 660-665;

  5. Piggot, J

    1. Isolation of glucagon antagonists by random molecular mutagenesis and screening.
      R A Smith, R Sisk, P Lockhart, S Mathewes, T Gilbert, K Walker and J Piggot
      Molecular Pharmacology May 1993, 43 (5) 741-748;

  6. Pregenzer, J F

    1. Comparison of interactions of [3H]muscimol, t-butylbicyclophosphoro[35S]thionate, and [3H]flunitrazepam with cloned gamma-aminobutyric acidA receptors of the alpha 1 beta 2 and alpha 1 beta 2 gamma 2 subtypes.
      J F Pregenzer, W B Im, D B Carter and D R Thomsen
      Molecular Pharmacology May 1993, 43 (5) 801-806;

R

  1. Roth, B L

    1. A single point mutation (Phe340-->Leu340) of a conserved phenylalanine abolishes 4-[125I]iodo-(2,5-dimethoxy)phenylisopropylamine and [3H]mesulergine but not [3H]ketanserin binding to 5-hydroxytryptamine2 receptors.
      M S Choudhary, S Craigo and B L Roth
      Molecular Pharmacology May 1993, 43 (5) 755-761;

S

  1. Saederup, E

    1. Indomethacin/ibuprofen-like anti-inflammatory agents selectively potentiate the gamma-aminobutyric acid-antagonistic effects of several norfloxacin-like quinolone antibacterial agents on [35S]t-butylbicyclophosphorothionate binding.
      R F Squires and E Saederup
      Molecular Pharmacology May 1993, 43 (5) 795-800;

  2. Savchenko, A

    1. Extracellular localization of the benzothiazepine binding domain of L-type Ca2+ channels.
      S Hering, A Savchenko, C Strübing, M Lakitsch and J Striessnig
      Molecular Pharmacology May 1993, 43 (5) 820-826;

  3. Schofield, M A

    1. Isolation and expression of a cDNA coding for rat kidney cytosolic cysteine conjugate beta-lyase.
      S J Perry, M A Schofield, M MacFarlane, E A Lock, L J King, G G Gibson and P S Goldfarb
      Molecular Pharmacology May 1993, 43 (5) 660-665;

  4. Schultz, G

    1. Novel potent inhibitor of receptor-activated nonselective cation currents in HL-60 cells.
      D Krautwurst, J Hescheler, D Arndts, W Lösel, R Hammer and G Schultz
      Molecular Pharmacology May 1993, 43 (5) 655-659;

  5. Servant, G

    1. Photoaffinity labeling of subtype 2 angiotensin receptor of human myometrium.
      G Servant, G Boulay, R Bossé, E Escher and G Guillemette
      Molecular Pharmacology May 1993, 43 (5) 677-683;

  6. Sisk, R

    1. Isolation of glucagon antagonists by random molecular mutagenesis and screening.
      R A Smith, R Sisk, P Lockhart, S Mathewes, T Gilbert, K Walker and J Piggot
      Molecular Pharmacology May 1993, 43 (5) 741-748;

  7. Sissi, C

    1. Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects.
      P De Isabella, G Capranico, M Palumbo, C Sissi, A P Krapcho and F Zunino
      Molecular Pharmacology May 1993, 43 (5) 715-721;

  8. Sklar, L A

    1. Subsecond modulation of formyl peptide-linked guanine nucleotide-binding proteins by guanosine 5'-O-(3-thio)triphosphate in permeabilized neutrophils.
      R R Neubig and L A Sklar
      Molecular Pharmacology May 1993, 43 (5) 734-740;

  9. Smith, R A

    1. Isolation of glucagon antagonists by random molecular mutagenesis and screening.
      R A Smith, R Sisk, P Lockhart, S Mathewes, T Gilbert, K Walker and J Piggot
      Molecular Pharmacology May 1993, 43 (5) 741-748;

  10. Squires, R F

    1. Indomethacin/ibuprofen-like anti-inflammatory agents selectively potentiate the gamma-aminobutyric acid-antagonistic effects of several norfloxacin-like quinolone antibacterial agents on [35S]t-butylbicyclophosphorothionate binding.
      R F Squires and E Saederup
      Molecular Pharmacology May 1993, 43 (5) 795-800;

  11. Stancel, G M

    1. Tamoxifen stimulates expression of the c-fos proto-oncogene in rodent uterus.
      J L Kirkland, L Murthy and G M Stancel
      Molecular Pharmacology May 1993, 43 (5) 709-714;

  12. Steel, M C

    1. Differential regulation of muscarinic receptor mRNA levels in neuroblastoma cells by chronic agonist exposure: a comparative polymerase chain reaction study.
      M C Steel and N J Buckley
      Molecular Pharmacology May 1993, 43 (5) 694-701;

  13. Striessnig, J

    1. Extracellular localization of the benzothiazepine binding domain of L-type Ca2+ channels.
      S Hering, A Savchenko, C Strübing, M Lakitsch and J Striessnig
      Molecular Pharmacology May 1993, 43 (5) 820-826;

  14. Strübing, C

    1. Extracellular localization of the benzothiazepine binding domain of L-type Ca2+ channels.
      S Hering, A Savchenko, C Strübing, M Lakitsch and J Striessnig
      Molecular Pharmacology May 1993, 43 (5) 820-826;

T

  1. Thomsen, D R

    1. Comparison of interactions of [3H]muscimol, t-butylbicyclophosphoro[35S]thionate, and [3H]flunitrazepam with cloned gamma-aminobutyric acidA receptors of the alpha 1 beta 2 and alpha 1 beta 2 gamma 2 subtypes.
      J F Pregenzer, W B Im, D B Carter and D R Thomsen
      Molecular Pharmacology May 1993, 43 (5) 801-806;

U

  1. Unsworth, C D

    1. Effects of agonists, partial agonists, and antagonists on the regulation of 5-hydroxytryptamine2 receptors in P11 cells.
      R C Ferry, C D Unsworth and P B Molinoff
      Molecular Pharmacology May 1993, 43 (5) 726-733;

W

  1. Walker, K

    1. Isolation of glucagon antagonists by random molecular mutagenesis and screening.
      R A Smith, R Sisk, P Lockhart, S Mathewes, T Gilbert, K Walker and J Piggot
      Molecular Pharmacology May 1993, 43 (5) 741-748;

Z

  1. Zunino, F

    1. Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects.
      P De Isabella, G Capranico, M Palumbo, C Sissi, A P Krapcho and F Zunino
      Molecular Pharmacology May 1993, 43 (5) 715-721;
Back to top

In this issue

Advertisement